Equity Overview
Price & Market Data
Price: $1.50
Daily Change: +$0.115 / 7.69%
Daily Range: $1.37 - $1.50
Market Cap: $107,568,096
Daily Volume: 607,420
Performance Metrics
1 Week: 8.33%
1 Month: 14.12%
3 Months: 21.54%
6 Months: -30.14%
1 Year: -56.41%
YTD: -50.66%
Company Details
Employees: 166
Sector: Health technology
Industry: Biotechnology
Country:
Details
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.